A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study design [0.03%]
AZUR-2研究设计：关于dMMR/ MSI-H可切除结肠癌新辅助和辅助达勒拉利姆ab治疗的III期临床试验
Naureen Starling,Elena Elez,John H Strickler et al.
Naureen Starling et al.
The role of perioperative immunotherapy as a chemotherapy-free option for patients with resectable mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colon cancer is evolving, with early-phase neoadjuvant studies reporti...
Clinical response of immunotherapy targeting programmed cell death receptor 1/programmed cell death ligand 1 in advanced signet-ring-cell gastric cancer [0.03%]
针对进展期印戒细胞胃癌免疫治疗靶向程序性细胞死亡受体1/程序性死亡配体1的临床疗效
Jie Liang,Xinhua Chen,Huayuan Liang et al.
Jie Liang et al.
Background: The clinical benefit of PD-1/PD-L1-based immunotherapy in gastric signet ring cell carcinoma (GSRCC) remains unclear. This study evaluated the efficacy of first-line immunotherapy in advanced GSRCC. ...
Safety and efficacy of preoperative chemotherapy for obstructive colon cancer with endoscopic stenting: SUCCEED study [0.03%]
术前化疗结合内镜支架置入治疗阻塞性结肠癌的疗效和安全性：SUCCEED研究
Ryosuke Mizuno,Rei Mizuno,Ryosuke Okamura et al.
Ryosuke Mizuno et al.
Aims: Self-expanding metal stents (SEMS) are widely used as a bridge to surgery in obstructive colon cancer, offering short-term benefits by reducing postoperative complications and avoiding emergency stoma creation. Addi...
Systemic immune-inflammation index combined with prognostic nutritional index for predicting cholangiocarcinoma PFS [0.03%]
系统免疫炎症指数联合预后营养指数用于预测胆管癌进展期患者的无进展生存期
Weijie Liu,Mingjun Zhang
Weijie Liu
Aims: To explore the prognostic value of the combined SII-PNI (Systemic Immune-Inflammation Index + Prognostic Nutritional Index) in cholangiocarcinoma (CCA) patients. ...
Plasma endogenous metabolome as superior biomarkers for adverse effects compared to drug and its metabolites [0.03%]
血浆内源性代谢组可作为预测不良反应的生物标志物优于药物及其代谢产物
Mingming Li,Tao Yan,Jiani Chen et al.
Mingming Li et al.
Aims: This study aims to assess whether pre-chemotherapy endogenous plasma metabolome can offer improved predictive values for Capecitabine chemotherapy-related adverse events (CRAEs). ...
Stage II colon cancer: does ChatGPT recommend more intensive adjuvant therapy? A comparison with MDT decisions [0.03%]
二期结肠癌：ChatGPT会推荐更强的辅助治疗吗？与多学科团队决策的比较
Zeliha Birsin,Seda Jeral,Selin Cebeci et al.
Zeliha Birsin et al.
Background: Adjuvant chemotherapy decision-making in stage II colon cancer remains challenging. Although multidisciplinary tumor boards (MDTs) guide treatment, their recommendations vary. Artificial intelligence (AI) tool...
The first United Arab Emirates expert consensus recommendations for the diagnosis and management of early and advanced non-small cell lung cancer [0.03%]
第一个阿拉伯联合酋长国专家共识推荐：早期和晚期非小细胞肺癌的诊断和治疗建议
Humaid Al Shamsi,Nadia Abdelwahed,Hassan Jaafar et al.
Humaid Al Shamsi et al.
Lung cancer is the first cause of mortality and the third most common cancer worldwide. In the United Arab Emirates (UAE), lung cancer ranks third in terms of cancer-related mortality and sixth in terms of incidence. In order to strengthen ...
Impact of radiation dose to immune cells on survival in patients with extensive-stage small cell lung cancer receiving consolidative thoracic radiotherapy after chemoimmunotherapy [0.03%]
免疫细胞辐射剂量对化疗免疫治疗后接受巩固性胸部放疗的广泛期小细胞肺癌患者生存影响的研究
Changxing Feng,Kang Wang,Fuhao Xu et al.
Changxing Feng et al.
Background: Consolidative thoracic radiotherapy (RT) following chemo-immunotherapy is increasingly used in extensive-stage small cell lung cancer (ES-SCLC). This study investigates the prognostic value of the estimated ra...
OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy [0.03%]
OPERA-01：一项palazestrant治疗CDK4/6抑制剂治疗后ER阳性、HER2阴性晚期乳腺癌患者的III期临床研究
Barbara Pistilli,Meritxell Bellet Ezquerra,Lucia Del Mastro et al.
Barbara Pistilli et al.
Endocrine therapy (ET) resistance is a major concern when treating estrogen receptor-positive (ER+) human epidermal growth factor receptor 2-negative (HER2-) breast cancer. A combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) a...